SGK3 Activators
The chemical class of SGK3 activators is characterized by compounds that modulate the activity of Serum/Glucocorticoid-Regulated Kinase 3 (SGK3), a kinase involved in diverse cellular processes. While direct activators specific to SGK3 may not be extensively documented, several chemicals indirectly influence SGK3 activation by targeting key signaling pathways. Wortmannin and LY294002 are inhibitors of phosphoinositide 3-kinase (PI3K), a crucial upstream regulator of SGK3. These compounds disrupt the PI3K/Akt pathway, influencing SGK3 activation indirectly. Similarly, Akt Inhibitor VIII and MK-2206 directly target Akt, another kinase in the PI3K/Akt pathway, impacting SGK3 activity through this regulatory cascade. GSK650394 is a selective inhibitor of SGK1 and SGK3, offering a direct approach to modulate SGK family members and understand SGK3-specific functions. Torin 1, PI-103, and BAY 1125976 act on mTOR, a downstream component of the PI3K/Akt pathway, affecting SGK3 activity indirectly.
BI-D1870 and SGI-1776 target p90 ribosomal S6 kinase (RSK) and Pim-1, respectively, which are downstream effectors of the MAPK and PI3K/Akt pathways. By influencing these pathways, these compounds indirectly modulate SGK3 activation. In summary, the chemical class of SGK3 activators comprises compounds that intervene in key signaling pathways such as PI3K/Akt, mTOR, and MAPK, providing valuable tools to dissect SGK3-specific functions and explore the intricate regulatory network governing SGK3 activity within cellular contexts. The indirect modulation of SGK3 by these compounds highlights the complexity of its regulatory mechanisms and offers insights into potential avenues for targeted interventions in cellular processes regulated by SGK3.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. It influences the PI3K/Akt pathway, and since SGK3 is downstream of Akt, Wortmannin indirectly affects SGK3 activation by inhibiting the PI3K pathway, a key regulator of SGK3 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, impacting the PI3K/Akt pathway. Similar to Wortmannin, LY294002 indirectly modulates SGK3 activity by suppressing the PI3K pathway, which plays a role in the activation of SGK3. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
This compound directly inhibits Akt, a kinase upstream of SGK3 in the PI3K/Akt pathway. By inhibiting Akt, AKT Inhibitor VIII disrupts the activation cascade, indirectly influencing SGK3 activity. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is an allosteric Akt inhibitor. Akt is an upstream regulator of SGK3, and inhibition of Akt by MK-2206 indirectly modulates SGK3 activity. | ||||||
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $187.00 $769.00 | 8 | |
GSK650394 is a selective inhibitor of SGK1 and SGK3. While it directly targets SGK family members, its use may provide insights into SGK3-specific functions and indirectly regulate SGK3 activity within cellular contexts. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is an inhibitor of mTOR, a kinase involved in the regulation of SGK3. By targeting mTOR, Torin 1 indirectly modulates SGK3 activity through the disruption of downstream signaling pathways. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual PI3K/mTOR inhibitor. Its impact on both PI3K and mTOR signaling pathways indirectly influences SGK3 activation, as SGK3 is regulated by these pathways. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511 is an inhibitor of PI3K, impacting the PI3K/Akt pathway. Like other PI3K inhibitors, LY303511 indirectly modulates SGK3 activity by interfering with the activation cascade of PI3K and Akt. | ||||||